3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Gliosarcoma
12
Glioblastoma
12
Sarcoma
10
Central Nervous System Neoplasms
8
Astrocytoma
8
Brain Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Burkitt Lymphoma
6
Recurrence
5
Oligodendroglioma
5
Hodgkin Disease
5
Glioma
5
Dendritic Cell Sarcoma, Interdigitating
5
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Familial ependymoma
4
Ependymoma
4
Rhabdomyosarcoma
3
Primary Myelofibrosis
3
Osteosarcoma
3
Neoplasm Metastasis
3
Interventions
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
pembrolizumab
2
Ipilimumab
2
Immunoglobulin G
2
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
regorafenib
1
pemigatinib
1
eribulin
1
cabozantinib
1
brivanib
1
avelumab
1
X-Rays
1
Valproic Acid
1
Sirolimus
1
Radiosurgery
1
Mifepristone
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cryosurgery
1
Colony-Stimulating Factors
1
Clinical Trials, Phase II as Topic
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
sargramostim
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled